{"id":"NCT00168038","sponsor":"CSL Behring","briefTitle":"Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10","officialTitle":"An Open-label, Multicenter Study on the Efficacy and Safety of IgPro10 in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-12","primaryCompletion":null,"completion":"2006-02","firstPosted":"2005-09-14","resultsPosted":"2011-11-23","lastUpdate":"2011-11-23"},"enrollment":58,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Immune Thrombocytopenic Purpura"],"interventions":[{"type":"BIOLOGICAL","name":"Immunoglobulin Intravenous (Human)","otherNames":["Privigen","IgPro10"]}],"arms":[{"label":"IgPro10","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy, tolerability and safety of IgPro10 in the treatment of patients with chronic immune thrombocytopenic purpura (ITP). The main efficacy parameter is the proportion of patients responding to treatment by an increase of platelet count to â‰¥ 50 x 10\\^9/L.","primaryOutcome":{"measure":"Platelet Response","timeFrame":"7 days","effectByArm":[{"arm":"IgPro10","deltaMin":80.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":10},"locations":{"siteCount":17,"countries":["Germany","Italy","Poland","Russia","Ukraine","United Kingdom"]},"refs":{"pmids":["19635187"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":57},"commonTop":["Headache","Pyrexia","Epistaxis","Contusion","Petechiae"]}}